BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

174 related articles for article (PubMed ID: 4708457)

  • 1. Malignant hyperpyrexia. Further muscle studies in asymptomatic carriers identified by creatinine phosphokinase screening.
    Isaacs H; Barlow MB
    J Neurol Neurosurg Psychiatry; 1973 Apr; 36(2):228-43. PubMed ID: 4708457
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Central-core disease and malignant hyperpyrexia.
    Denborough MA; Dennett X; Anderson RM
    Br Med J; 1973 Feb; 1(5848):272-3. PubMed ID: 4265427
    [No Abstract]   [Full Text] [Related]  

  • 3. Malignant hyperpyrexia.
    Denborough MA
    Compr Ther; 1975 Dec; 1(8):51-6. PubMed ID: 770064
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Malignant hyperthermia with rigidity successfully treated with procainamide.
    Noble WH; McKee D; Gates B
    Anesthesiology; 1973 Oct; 39(4):450-1. PubMed ID: 4758355
    [No Abstract]   [Full Text] [Related]  

  • 5. Myopathy and malignant hyperpyrexia.
    Denborough MA; Ebeling P; King JO; Zapf P
    Lancet; 1970 May; 1(7657):1138-40. PubMed ID: 4192097
    [No Abstract]   [Full Text] [Related]  

  • 6. Malignant hyperpyrexia during anaesthesia: possible association with subclinical myopathy.
    Isaacs H; Barlow MB
    Br Med J; 1970 Jan; 1(5691):275-7. PubMed ID: 5416617
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Enzyme changes, myoglobinuria and muscular necrosis following malignant hyperpyrexia].
    Zinganell K; Kreutz FH; Suchenwirth R
    Z Prakt Anasth Wiederbeleb Intensivther; 1972 Jun; 7(3):161-7. PubMed ID: 5073635
    [No Abstract]   [Full Text] [Related]  

  • 8. Identification of susceptibility to malignant hyperpyrexia.
    Moulds RF; Denborough MA
    Br Med J; 1974 May; 2(5913):245-7. PubMed ID: 4827071
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pathology of malignant hyperpyrexia.
    Br Med J; 1973 Feb; 1(5848):249. PubMed ID: 4685313
    [No Abstract]   [Full Text] [Related]  

  • 10. Evaluation of creatinine phosphokinase in screening patients for malignant hyperpyrexia.
    Ellis FR; Clarke IM; Modgill M; Currie S; Harriman DG
    Br Med J; 1975 Aug; 3(5982):511-3. PubMed ID: 1164612
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Hypokalemic myopathy associated with primary aldosteronism and glycyrrhizine-induced pseudoaldosteronism.
    Ishikawa S; Saito T; Okada K; Atsumi T; Kuzuya T
    Endocrinol Jpn; 1985 Dec; 32(6):793-802. PubMed ID: 3914413
    [TBL] [Abstract][Full Text] [Related]  

  • 12. 'Picture frame' fibres in a carrier of the trait for malignant hyperpyrexia.
    Isaacs H; Heffron JJ; Badenhorst M
    S Afr Med J; 1975 Nov; 49(46):1923-6. PubMed ID: 795
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Editorial: Malignant hyperthermia: a pharmacogenetic disease of skeletal and cardiac muscle.
    Britt BA
    N Engl J Med; 1974 May; 290(20):1140-2. PubMed ID: 4274465
    [No Abstract]   [Full Text] [Related]  

  • 14. Malignant hyperpyrexia myopathy.
    Harriman DG; Sumner DW; Ellis FR
    Q J Med; 1973 Oct; 42(168):639-64. PubMed ID: 4802524
    [No Abstract]   [Full Text] [Related]  

  • 15. Malignant hyperpyrexia.
    Ellis FR
    Anaesthesia; 1973 May; 28(3):245-52. PubMed ID: 4713948
    [No Abstract]   [Full Text] [Related]  

  • 16. Malignant hyperthermia and central core disease: analysis of two families with heterogeneous clinical expression.
    Romero NB; Nivoche Y; Lunardi J; Bruneau B; Cheval MA; Hillaire D; Fardeau M
    Neuromuscul Disord; 1993; 3(5-6):547-51. PubMed ID: 8186709
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Chronic myopathy in a patient suspected of carrying two malignant hyperthermia susceptibility (MHS) mutations.
    Deufel T; Müller-Felber W; Pongratz DE; Hübner G; Johnson K; Iaizzo PA; Lehmann-Horn F
    Neuromuscul Disord; 1992; 2(5-6):389-96. PubMed ID: 1300187
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Clinical and morphological findings in a case of malignant hyperthermia (author's transl)].
    Faber P; Gullotta F; Koenen FW
    Dtsch Med Wochenschr; 1975 Sep; 100(39):1974-6. PubMed ID: 1157706
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Morphological and biochemical defects in muscles of human carriers of the malignant hyperthermia syndrome.
    Isaacs H; Heffron JJ
    Br J Anaesth; 1975 Apr; 47(4):475-81. PubMed ID: 124580
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Screening of malignant hyperthermia susceptible families by creatine phosphokinase measurement and other clinical investigations.
    Britt BA; Endrenyi L; Peters PL; Kwong FH; Kadijevic L
    Can Anaesth Soc J; 1976 May; 23(3):263-84. PubMed ID: 938964
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.